Skip to main content

Insights, news and articles from the frontline of Pharma

The Ripple Effects of Healthcare Reforms in Germany: A Reduced Free Pricing Period
The Ripple Effects of Healthcare Reforms in Germany: A Reduced Free Pricing Period

The Ripple Effects of Healthcare Reforms in Germany: A Reduced Free Pricing Period

10 min
Preparing for successful market access and HTA assessments in Europe
Preparing for successful market access and HTA assessments in Europe

Preparing for successful market access and HTA assessments in Europe

13 min
What are the pricing and repricing mechanisms in Japan’s P&R system that pharma must understand when considering a launch in Japan?
What are the pricing and repricing mechanisms in Japan’s P&R system that pharma must understand when considering a launch in Japan?

What are the pricing and repricing mechanisms in Japan’s P&R system that pharma must understand when considering a launch in Japan?

15 min
How Should Pharmaceutical Companies Plan Launch Strategies in Europe’s Cost-Saving Environment?
How Should Pharmaceutical Companies Plan Launch Strategies in Europe’s Cost-Saving Environment?

How Should Pharmaceutical Companies Plan Launch Strategies in Europe’s Cost-Saving Environment?

20 min
The evolving role of provider, payer, and patients in biosimilar adoption - how does this affect successful commercialization of biosimilars in EU4+UK?
Access for all
The evolving role of provider, payer, and patients in biosimilar adoption - how does this affect successful commercialization of biosimilars in EU4+UK?

The evolving role of provider, payer, and patients in biosimilar adoption - how does this affect successful commercialization of biosimilars in EU4+UK?

22 min
The Ripple Effects of Healthcare Reforms in Germany: A Reduced Free Pricing Period
The Ripple Effects of Healthcare Reforms in Germany: A Reduced Free Pricing Period

The Ripple Effects of Healthcare Reforms in Germany: A Reduced Free Pricing Period

10 min
Collaborating for better outcomes: How can value-based partnerships unlock value across stakeholder groups and elevate pharma’s role within healthcare ecosystems?
Collaborating for better outcomes: How can value-based partnerships unlock value across stakeholder groups and elevate pharma’s role within healthcare ecosystems?

Collaborating for better outcomes: How can value-based partnerships unlock value across stakeholder groups and elevate pharma’s role within healthcare ecosystems?

15 min
Preparing Healthcare Systems for Broader CGT Access: What Needs to Change for Pharma, Healthcare Systems, and Patients so All Benefit from Cell & Gene Therapies?
Preparing Healthcare Systems for Broader CGT Access: What Needs to Change for Pharma, Healthcare Systems, and Patients so All Benefit from Cell & Gene Therapies?

Preparing Healthcare Systems for Broader CGT Access: What Needs to Change for Pharma, Healthcare Systems, and Patients so All Benefit from Cell & Gene Therapies?

17 min
Pharmaceutical corporate-sponsored digital incubators – is this an answer to the perennial question of how to digitize pharmaceutical companies?
Pharmaceutical corporate-sponsored digital incubators – is this an answer to the perennial question of how to digitize pharmaceutical companies?

Pharmaceutical corporate-sponsored digital incubators – is this an answer to the perennial question of how to digitize pharmaceutical companies?

6 min
The evolution of Early Access Programmes (EAPs) design for gene therapies and single-administration treatments
The evolution of Early Access Programmes (EAPs) design for gene therapies and single-administration treatments

The evolution of Early Access Programmes (EAPs) design for gene therapies and single-administration treatments

5 min
The future of patient care amidst a growing digital health landscape
The future of patient care amidst a growing digital health landscape

The future of patient care amidst a growing digital health landscape

5 min
FDA’s Newest Contribution to the Real-World Evidence Revolution: Innovative Frameworks to Streamline Regulatory Submissions
FDA’s Newest Contribution to the Real-World Evidence Revolution: Innovative Frameworks to Streamline Regulatory Submissions

FDA’s Newest Contribution to the Real-World Evidence Revolution: Innovative Frameworks to Streamline Regulatory Submissions

6 min
The role of artificial intelligence in revolutionising drug discovery
The role of artificial intelligence in revolutionising drug discovery

The role of artificial intelligence in revolutionising drug discovery

6 min
Workshops that actually work: Essential principles for delivering strategy workshops that bond, engage and motivate biopharma teams
Workshops that actually work: Essential principles for delivering strategy workshops that bond, engage and motivate biopharma teams

Workshops that actually work: Essential principles for delivering strategy workshops that bond, engage and motivate biopharma teams

8 min
Royalties in pharma: A closer look at the company which owns a stake in a quarter of all blockbuster drugs, and the growing significance of the model they created
Royalties in pharma: A closer look at the company which owns a stake in a quarter of all blockbuster drugs, and the growing significance of the model they created

Royalties in pharma: A closer look at the company which owns a stake in a quarter of all blockbuster drugs, and the growing significance of the model they created

7 min
Continental drift: Why pharma companies are pulling away from ‘innovation unfriendly’ Europe, and how biopharma leaders can adapt
Continental drift: Why pharma companies are pulling away from ‘innovation unfriendly’ Europe, and how biopharma leaders can adapt

Continental drift: Why pharma companies are pulling away from ‘innovation unfriendly’ Europe, and how biopharma leaders can adapt

8 min
Uncertain fate: The death of allogeneic cell therapy?
Uncertain fate: The death of allogeneic cell therapy?

Uncertain fate: The death of allogeneic cell therapy?

7 min
Women’s health is greater than Femtech – and the opportunity is huge. 
Women’s health is greater than Femtech – and the opportunity is huge. 

Women’s health is greater than Femtech – and the opportunity is huge. 

4 min
Is DiGA the way forward? – What does the optimal reimbursement model look like?
Is DiGA the way forward? – What does the optimal reimbursement model look like?

Is DiGA the way forward? – What does the optimal reimbursement model look like?

3 min
AI-Powered Drug Discovery – buzzword or the future?
AI-Powered Drug Discovery – buzzword or the future?

AI-Powered Drug Discovery – buzzword or the future?

3 min
Gene Therapies: Can the industry keep up its momentum or will it burn out?
Gene Therapies: Can the industry keep up its momentum or will it burn out?

Gene Therapies: Can the industry keep up its momentum or will it burn out?

6 min
The cutting edge of biotech: the continuous drive to achieve next-gen greatness
The cutting edge of biotech: the continuous drive to achieve next-gen greatness

The cutting edge of biotech: the continuous drive to achieve next-gen greatness

6 min
Access for one, access for all: if no longer rare, how will biotech ensure sustainable access to CGTs to the masses?
Access for one, access for all: if no longer rare, how will biotech ensure sustainable access to CGTs to the masses?

Access for one, access for all: if no longer rare, how will biotech ensure sustainable access to CGTs to the masses?

6 min
Throw it against the wall and see what sticks; Players testing their ‘new’ molecular entities in numerous immuno-oncology or autoimmune settings concurrently
Throw it against the wall and see what sticks; Players testing their ‘new’ molecular entities in numerous immuno-oncology or autoimmune settings concurrently

Throw it against the wall and see what sticks; Players testing their ‘new’ molecular entities in numerous immuno-oncology or autoimmune settings concurrently

3 min
Assembling all the bits and pieces – tackling capacity constraints for the successful rollout for neurological therapies
Assembling all the bits and pieces – tackling capacity constraints for the successful rollout for neurological therapies

Assembling all the bits and pieces – tackling capacity constraints for the successful rollout for neurological therapies

3 min
Venturing Into the Unknown: How Pharma is Embracing Neuroscience R&D After Decades of Failure
Venturing Into the Unknown: How Pharma is Embracing Neuroscience R&D After Decades of Failure

Venturing Into the Unknown: How Pharma is Embracing Neuroscience R&D After Decades of Failure

3 min
To deliver cell and gene therapies, pharma needs to spend more time with patients
To deliver cell and gene therapies, pharma needs to spend more time with patients

To deliver cell and gene therapies, pharma needs to spend more time with patients

4 min
Oral therapies – what role should patient support programs (PSPs) play?
Oral therapies – what role should patient support programs (PSPs) play?

Oral therapies – what role should patient support programs (PSPs) play?

3 min
Customer experience in healthcare: Should Pharma take a page from the Tech industry?
Customer experience in healthcare: Should Pharma take a page from the Tech industry?

Customer experience in healthcare: Should Pharma take a page from the Tech industry?

3 min
Diversifying Clinical Trials for Regulatory Success – One Size Does Not Fit All
Diversifying Clinical Trials for Regulatory Success – One Size Does Not Fit All

Diversifying Clinical Trials for Regulatory Success – One Size Does Not Fit All

3 min
Patient-Centricity in Drug Development – Getting it Right the First Time
Patient-Centricity in Drug Development – Getting it Right the First Time

Patient-Centricity in Drug Development – Getting it Right the First Time

3 min
Talking the Talk: Pharma’s Role in Addressing Social Determinants of Health
Talking the Talk: Pharma’s Role in Addressing Social Determinants of Health

Talking the Talk: Pharma’s Role in Addressing Social Determinants of Health

3 min
Facing reality: the power behind Real World Evidence (RWE) and how to keep up
Facing reality: the power behind Real World Evidence (RWE) and how to keep up

Facing reality: the power behind Real World Evidence (RWE) and how to keep up

5 min
FDA’s Project Optimus – A revolution of the oncology clinical development paradigm through a reform of drug dose optimization
FDA’s Project Optimus – A revolution of the oncology clinical development paradigm through a reform of drug dose optimization

FDA’s Project Optimus – A revolution of the oncology clinical development paradigm through a reform of drug dose optimization

3 min
Liquid Biopsies: Bio-marking an Era of Precision Medicine
Liquid Biopsies: Bio-marking an Era of Precision Medicine

Liquid Biopsies: Bio-marking an Era of Precision Medicine

3 min
Hail the Slow Burner – now’s the time to fire up your Cross-Portfolio Competitive Intelligence Function
Hail the Slow Burner – now’s the time to fire up your Cross-Portfolio Competitive Intelligence Function

Hail the Slow Burner – now’s the time to fire up your Cross-Portfolio Competitive Intelligence Function

14 min
Jumping on the bandwagon – Western pharma seeks to capture the innovation erupting from China through hands-on partnering initiatives
Jumping on the bandwagon – Western pharma seeks to capture the innovation erupting from China through hands-on partnering initiatives

Jumping on the bandwagon – Western pharma seeks to capture the innovation erupting from China through hands-on partnering initiatives

8 min
A Sleeping CGT Giant Awakening: Will China Partner or Pioneer?
A Sleeping CGT Giant Awakening: Will China Partner or Pioneer?

A Sleeping CGT Giant Awakening: Will China Partner or Pioneer?

7 min
Digital Health & Patient Data: Elevating the ceiling across Pharma’s entire value chain
Digital Health & Patient Data: Elevating the ceiling across Pharma's entire value chain
Digital Health & Patient Data: Elevating the ceiling across Pharma’s entire value chain

Digital Health & Patient Data: Elevating the ceiling across Pharma’s entire value chain

5 min
Could digital patient services influence future payer negotiations?
Could digital patient services influence future payer negotiations?
Could digital patient services influence future payer negotiations?

Could digital patient services influence future payer negotiations?

6 min
How is pharma using digital clinical trials to outpace its competitors?
How is pharma using digital clinical trials to outpace its competitors?
How is pharma using digital clinical trials to outpace its competitors?

How is pharma using digital clinical trials to outpace its competitors?

4 min
The Future of Work in the Life Sciences: How Eradigm Are Leading the Charge Post-Covid
The Future of Work in the Life Sciences: How Eradigm Are Leading the Charge Post-Covid

The Future of Work in the Life Sciences: How Eradigm Are Leading the Charge Post-Covid

7 min
Accelerating into Hyperspace: From automation to in-process sampling – how novel approaches in CAR-T manufacture could deliver greater speed
Accelerating into Hyperspace: From automation to in-process sampling – how novel approaches in CAR-T manufacture could deliver greater speed

Accelerating into Hyperspace: From automation to in-process sampling – how novel approaches in CAR-T manufacture could deliver greater speed

4 min
Venturing Out: How advances in remote monitoring solutions and tools may be the key to widening CAR-T treatment into the community
Venturing Out: How advances in remote monitoring solutions and tools may be the key to widening CAR-T treatment into the community
Venturing Out: How advances in remote monitoring solutions and tools may be the key to widening CAR-T treatment into the community

Venturing Out: How advances in remote monitoring solutions and tools may be the key to widening CAR-T treatment into the community

6 min
From last-line to frontline: Clinical trials and a growing chorus of expert opinion suggest CAR-T’s true value lies in an early-line treatment
From last-line to frontline: Clinical trials and a growing chorus of expert opinion suggest CAR-T’s true value lies in an early-line treatment
From last-line to frontline: Clinical trials and a growing chorus of expert opinion suggest CAR-T’s true value lies in an early-line treatment

From last-line to frontline: Clinical trials and a growing chorus of expert opinion suggest CAR-T’s true value lies in an early-line treatment

4 min
Turning pharma inside out: It’s time big pharma applied the same curiosity to its purpose as it does to the science
Turning pharma inside out: It’s time big pharma applied the same curiosity to its purpose as it does to the science

Turning pharma inside out: It’s time big pharma applied the same curiosity to its purpose as it does to the science

4 min
Digital Therapeutics: big pharma faces an identity crisis.
Eradigm Digital fuel
Digital Therapeutics: big pharma faces an identity crisis.

Digital Therapeutics: big pharma faces an identity crisis.

5 min
Value-based healthcare is here to stay – Pharma needs to embrace it, or risk getting cut out of the conversation
Value-based healthcare is here to stay – Pharma needs to embrace it, or risk getting cut out of the conversation

Value-based healthcare is here to stay – Pharma needs to embrace it, or risk getting cut out of the conversation

5 min
The hare and the tortoise race to market – pharma needs to re-think responsible trial innovation for improved patient access, rather than just speed
The hare and the tortoise race to market – pharma needs to re-think responsible trial innovation for improved patient access, rather than just speed

The hare and the tortoise race to market – pharma needs to re-think responsible trial innovation for improved patient access, rather than just speed

7 min
Putting patients first (or else) – Pharma needs to shift into gear and design patient support programs that benefit the entire healthcare ecosystem vs their bottom line
Putting patients first (or else) – Pharma needs to shift into gear and design patient support programs that benefit the entire healthcare ecosystem vs their bottom line

Putting patients first (or else) – Pharma needs to shift into gear and design patient support programs that benefit the entire healthcare ecosystem vs their bottom line

6 min
Lifesavers to legacy – COVID-19 has put partnership and innovation back at the heart of pharma
Lifesavers to legacy – COVID-19 has put partnership and innovation back at the heart of pharma

Lifesavers to legacy – COVID-19 has put partnership and innovation back at the heart of pharma

7 min
The winds of change are blowing from the East: why and how Western pharma should get ready to sow the seeds now
Eradigm Storm
The winds of change are blowing from the East: why and how Western pharma should get ready to sow the seeds now

The winds of change are blowing from the East: why and how Western pharma should get ready to sow the seeds now

5 min
How to shapeshift through partnering – rewriting fate through visionary leaps and agile collaborations
How to shapeshift through partnering – rewriting fate through visionary leaps and agile collaborations

How to shapeshift through partnering – rewriting fate through visionary leaps and agile collaborations

5 min
How the COVID crisis gave pharma its mojo back, and how to keep it
How the COVID crisis gave pharma its mojo back, and how to keep it

How the COVID crisis gave pharma its mojo back, and how to keep it

7 min
To win in CAR-T you need much more than data – the customer is King
To win in CAR-T you need much more than data – the customer is King

To win in CAR-T you need much more than data – the customer is King

4 min
It is time for pharma to pick a side – choose public health or get left out in the cold
It is time for pharma to pick a side – choose public health or get left out in the cold

It is time for pharma to pick a side – choose public health or get left out in the cold

5 min
From binge-eating to lifestyle change: pharma competitive strategy
From binge-eating to lifestyle change: pharma competitive strategy

From binge-eating to lifestyle change: pharma competitive strategy

5 min

Our Mission     Our Services     Our Team     Insights     Careers     Contact Us

Our Mission     Our Services     Our Team     Insights     Careers     Contact Us